| Related Articles |
When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.
Expert Rev Anticancer Ther. 2015;15(7):761-3
Authors: Gallucci G, Tartarone A, Lombardi L, Aieta M
Abstract
Crizotinib is an orally active multi-target tyrosine kinase inhibitor which is the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Common adverse events in clinical trials with crizotinib included visual disorders, nausea-vomiting, diarrhea and elevated transaminases. Less common toxicities are emerging, such as bradycardia and QT interval prolongation. We report on a case of a presyncopal episode which occurred under crizotinib and metoclopramide treatment.
PMID: 25961872 [PubMed - indexed for MEDLINE]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1PfQZyY
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου